Unione Europea - inglese - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,

Unione Europea - inglese - EMA (European Medicines Agency)

sandoz gmbh - pregabalin - anxiety disorders; epilepsy - antiepileptics, - epilepsypregabalin sandoz gmbh is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.generalised anxiety disorderpregabalin sandoz gmbh is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Unione Europea - inglese - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - other dermatological preparations - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

Malta - inglese - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - imatinib mesilate - film-coated tablet - imatinib mesilate 100 mg - antineoplastic agents

Malta - inglese - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - imatinib mesilate - film-coated tablet - imatinib mesilate 400 mg - antineoplastic agents

Malta - inglese - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 20 mg - urologicals

Malta - inglese - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 5 mg - urologicals

Malta - inglese - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - tadalafil - film-coated tablet - tadalafil 10 mg - urologicals

Malta - inglese - Medicines Authority

biomo pharma gmbh josef-dietzgen-straße 3, d-53773, hennef,, germany - tadalafil - film-coated tablet - tadalafil 20 mg - urologicals

Malta - inglese - Medicines Authority

biomo pharma gmbh josef-dietzgen-straße 3, d-53773, hennef,, germany - tadalafil - film-coated tablet - tadalafil 5 mg - urologicals